GNPX Morning Update - Major News Yesterday Plus New Stock Profile Arrives 4:00PM EST Today or 9:30AM Tomorrow
Join My Quick SMS Update System - Sign Up Info Below
Did you see yesterday's major news release on GNPX? If you didn't, read it now:
Genprex and University of Pittsburgh Sign Exclusive License Agreement for Potentially Curative Gene Therapy Candidate for Diabetes
- Company licenses patented diabetes gene therapy technology designed by researchers at the University of Pittsburgh
- Results from in vivo animal studies indicate that normal glucose levels in the blood may be restored for an extended period of time
- Company plans to partner for the clinical development and commercialization of this therapy in the U.S. and internationally
AUSTIN, Texas & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Genprex, Inc. (“Genprex” or the “Company”) (NASDAQ: GNPX), a clinical-stage gene therapy company developing potentially life-changing technologies for patients with cancer and other serious diseases, today announced that it signed an exclusive license agreement with the University of Pittsburgh for a diabetes gene therapy that may have the potential to cure Type 1 and Type 2 diabetes, which together currently affect approximately 30.3 million people in the U.S, or 9 percent of the U.S. population.
Read the full press release here.
But, that's not all...
I've uncovered a new profile out of the lucrative beverage industry. This low float stock idea could be a major breakout candidate because of 4 key catalysts I've uncovered.
I'm delivering your full report at 4:00PM EST today or 9:30AM Thursday. Clear your schedule now.
Also, if you want to make sure you get this stock profile as quickly as possible, take care of these simple steps: